Senesco Technologies, Inc. (SNT) - 500 Beiträge pro Seite
eröffnet am 21.03.06 19:22:14 von
neuester Beitrag 28.12.06 13:02:41 von
neuester Beitrag 28.12.06 13:02:41 von
Beiträge: 21
ID: 1.048.946
ID: 1.048.946
Aufrufe heute: 0
Gesamt: 1.194
Gesamt: 1.194
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 01.04.24, 10:52 | 162 | |
| gestern 19:37 | 136 | |
| gestern 21:20 | 135 | |
| vor 1 Stunde | 120 | |
| 22.06.20, 20:50 | 84 | |
| gestern 22:23 | 78 | |
| heute 00:34 | 74 | |
| gestern 21:47 | 70 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.737,36 | -0,56 | 198 | |||
| 2. | 2. | 147,05 | -1,92 | 95 | |||
| 3. | 7. | 6,6320 | -1,43 | 70 | |||
| 4. | 5. | 0,1810 | -1,90 | 51 | |||
| 5. | Neu! | 713,65 | -23,14 | 46 | |||
| 6. | 8. | 3,7700 | +0,80 | 45 | |||
| 7. | 17. | 7,2900 | -0,21 | 43 | |||
| 8. | 4. | 2.390,60 | 0,00 | 41 |
Feedback
Profile:Senesco Technologies, Inc. engages in the research and development of genetic technologies for commercial agriculture.The company develops technology for the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. It develops its technologies for the commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields, and reducing the harmful effects of environmental stresses, like drought. The company also engages in the development of technologies, which may address the various human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma, and cardiovascular disease. It licenses its technology to agricultural companies. Senesco Technologies is based in New Brunswick, New Jersey.
http://www.senesco.com/
http://www.senesco.com/
mhh
auch im ethanol bereich!!!
http://www.senesco.com/broin.htm
In October, 2004, we entered into a license agreement with the Broin Companies to license our proprietary gene technology to Broin to improve aspects of Broin’s ethanol production capabilities. We will receive an annual payment for each Broin facility that incorporates our technology.
auch im ethanol bereich!!!
http://www.senesco.com/broin.htm
In October, 2004, we entered into a license agreement with the Broin Companies to license our proprietary gene technology to Broin to improve aspects of Broin’s ethanol production capabilities. We will receive an annual payment for each Broin facility that incorporates our technology.
Senesco`s Technology Increases Pancreatic Islet Cell Survivability in Animal Study
Wednesday March 22, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 22, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX: SNT - News) announced today that a preclinical animal study has shown that the Company`s proprietary gene technology increases the survivability of islets isolated for transplantation. Islets are the insulin producing cells located in the mammalian pancreas.
Diabetes is a growing health problem in the developed world, with daily insulin injections being a common primary treatment. The transplantation of the insulin-producing islets from donors has progressed during the past five years. Most promising is the fact that patients whose condition is difficult to control with insulin have a rapid return to normal blood glucose upon islet transplantation. Unfortunately, islet transplantation typically requires cells from two donors and a large number of islets die during harvest due to isolation methods requiring digestive enzymes.
Dr. Eli C. Lewis, working in the laboratory of Dr. Charles Dinarello at the University of Colorado, investigated the role of the Company`s eIF-5A1 (otherwise referred to as "Factor 5A") gene technology during the process of islet isolation for transplantation using a well-established mouse model. The team used a small interfering RNA ("siRNA") that downregulates expression of eIF-5A1, which the Company has shown reduces cell death in a variety of models. The researchers observed a significant increase in the survival of insulin-producing islets when mice received an infusion of the siRNA to eIF-51A compared to a control siRNA. In a concurrent study, the investigators showed that death of islets resulting from exposure to IL-1beta and interferon-gamma was also significantly reduced, meaning more viable islets remained.
Dr. Dinarello, a member of the Company`s Scientific Advisory Board, said of the results, "The implications of these results for human islets transplantation are important since this siRNA can yield more viable (live) islets while increasing the number of transplantations that can be performed. Presently, one of the major drawbacks of islet transplantation is the low number of live islets that can be obtained for transplantation. The promise of this novel approach will be welcome to the field."
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners` products. Senesco is headquartered in New Brunswick, New Jersey.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company`s gene technology; the approval of the Company`s patent applications; the successful implementation of the Company`s research and development programs and joint ventures; the success of the Company`s license agreements; the acceptance by the market of the Company`s products; success of the Company`s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company`s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company`s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Senesco Technologies, Inc.
Bruce Galton, Chief Executive Officer, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, 212-838-3777
Kim Sutton Golodetz
kgolodetz@lhai.com
or
Anne Marie Fields
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
Wednesday March 22, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 22, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX: SNT - News) announced today that a preclinical animal study has shown that the Company`s proprietary gene technology increases the survivability of islets isolated for transplantation. Islets are the insulin producing cells located in the mammalian pancreas.
Diabetes is a growing health problem in the developed world, with daily insulin injections being a common primary treatment. The transplantation of the insulin-producing islets from donors has progressed during the past five years. Most promising is the fact that patients whose condition is difficult to control with insulin have a rapid return to normal blood glucose upon islet transplantation. Unfortunately, islet transplantation typically requires cells from two donors and a large number of islets die during harvest due to isolation methods requiring digestive enzymes.
Dr. Eli C. Lewis, working in the laboratory of Dr. Charles Dinarello at the University of Colorado, investigated the role of the Company`s eIF-5A1 (otherwise referred to as "Factor 5A") gene technology during the process of islet isolation for transplantation using a well-established mouse model. The team used a small interfering RNA ("siRNA") that downregulates expression of eIF-5A1, which the Company has shown reduces cell death in a variety of models. The researchers observed a significant increase in the survival of insulin-producing islets when mice received an infusion of the siRNA to eIF-51A compared to a control siRNA. In a concurrent study, the investigators showed that death of islets resulting from exposure to IL-1beta and interferon-gamma was also significantly reduced, meaning more viable islets remained.
Dr. Dinarello, a member of the Company`s Scientific Advisory Board, said of the results, "The implications of these results for human islets transplantation are important since this siRNA can yield more viable (live) islets while increasing the number of transplantations that can be performed. Presently, one of the major drawbacks of islet transplantation is the low number of live islets that can be obtained for transplantation. The promise of this novel approach will be welcome to the field."
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners` products. Senesco is headquartered in New Brunswick, New Jersey.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company`s gene technology; the approval of the Company`s patent applications; the successful implementation of the Company`s research and development programs and joint ventures; the success of the Company`s license agreements; the acceptance by the market of the Company`s products; success of the Company`s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company`s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company`s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Senesco Technologies, Inc.
Bruce Galton, Chief Executive Officer, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, 212-838-3777
Kim Sutton Golodetz
kgolodetz@lhai.com
or
Anne Marie Fields
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
Trading Spotlight
Senesco's Technology Shows Reduction of Two Important Indicators of HIV-1 Replication in Human Cell Line Studies
Wednesday March 29, 8:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 29, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today that results from human cell line tests have shown that the Company's eukaryotic translation initiation Factor 5A1 ("Factor 5A1" or "eIF-5A1") gene technology reduces the amounts of p24 and IL-8 by approximately 50 percent in HIV-infected cells. The levels of p24, a core protein in HIV cells, and IL-8, a proinflammatory cytokine, rise proportionately with increased HIV replication, making both of them standard indicators of HIV-1 infection.
ADVERTISEMENT
Using a chronically HIV-1 infected human cell line, researchers in Dr. Leland Shapiro's lab at the University of Colorado at Denver and Health Sciences Center performed the studies for the Company. The HIV cell line was transfected with a small interfering RNA ("siRNA") to eIF-5A1 and then levels of p24 or IL-8 were measured, in separate assays, 72 hours later. Reduced levels of p24 and IL-8 correlate to suppressed replication of HIV-1.
"Although these results represent early stages of investigation, they are promising for two reasons. First, these proof-of-concept studies suggest that eIF-5A1 is a viable target for HIV drug discovery. Second, eIF-5A1 is a molecule made by the cell and not the virus. Therefore, the eIF-5A1 target does not mutate and an anti-HIV strategy using this target may not be hampered by resistance brought about by viral mutation," Shapiro said.
Bruce Galton, president and CEO of Senesco, commented, "We are very pleased with these initial data pertaining to suppressing viral replication in this HIV model. Viral replication is both an interesting and important new research area for the Company. These data reaffirm the potential broad applicability of Factor 5A in a variety of diseases, adding to our preclinical data in cancer, inflammation and immune response."
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies
Bruce Galton, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies
Wednesday March 29, 8:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 29, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today that results from human cell line tests have shown that the Company's eukaryotic translation initiation Factor 5A1 ("Factor 5A1" or "eIF-5A1") gene technology reduces the amounts of p24 and IL-8 by approximately 50 percent in HIV-infected cells. The levels of p24, a core protein in HIV cells, and IL-8, a proinflammatory cytokine, rise proportionately with increased HIV replication, making both of them standard indicators of HIV-1 infection.
ADVERTISEMENT
Using a chronically HIV-1 infected human cell line, researchers in Dr. Leland Shapiro's lab at the University of Colorado at Denver and Health Sciences Center performed the studies for the Company. The HIV cell line was transfected with a small interfering RNA ("siRNA") to eIF-5A1 and then levels of p24 or IL-8 were measured, in separate assays, 72 hours later. Reduced levels of p24 and IL-8 correlate to suppressed replication of HIV-1.
"Although these results represent early stages of investigation, they are promising for two reasons. First, these proof-of-concept studies suggest that eIF-5A1 is a viable target for HIV drug discovery. Second, eIF-5A1 is a molecule made by the cell and not the virus. Therefore, the eIF-5A1 target does not mutate and an anti-HIV strategy using this target may not be hampered by resistance brought about by viral mutation," Shapiro said.
Bruce Galton, president and CEO of Senesco, commented, "We are very pleased with these initial data pertaining to suppressing viral replication in this HIV model. Viral replication is both an interesting and important new research area for the Company. These data reaffirm the potential broad applicability of Factor 5A in a variety of diseases, adding to our preclinical data in cancer, inflammation and immune response."
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies
Bruce Galton, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies
Ethanol Phantasie!!
http://www.senesco.com/broin.htm
http://www.senesco.com/broin.htm
Senesco's Technology Inhibits Tumor Development and Increases Longevity in Mouse Cancer Model
Thursday April 27, 6:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--April 27, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today the results of a study conducted in Dr. John Thompson's laboratory at the University of Waterloo in Ontario, Canada, in which mice injected with tumor-forming B16F0 melanoma cancer cells were treated with Senesco's proprietary gene, eIF-5A ("Factor 5A"). Tumors of adequate size formed in approximately nine days at which time treatment was initiated. Two control groups of nine mice each received placebo treatments and a test group of ten mice received Factor 5A, intratumorally, every other day. The median survival of the control mice was 7 days post-treatment, whereas, the mice that received Factor 5A treatment had a median survival of 25 days post-treatment (P less than 0.001). The enhanced survival time of the Factor 5A-treated mice equates to 3.5 fold or a 250% increase compared to the control mice. Two of the Factor 5A-treated mice are still alive, with one mouse in apparent complete remission. None of the control mice survived.
ADVERTISEMENT
In addition to this enhancement of survival, the tumors in the treated mice remained smaller and grew more slowly than those in the control mice.
Dr. Thompson, the Company's Executive Vice President of Research and Development, commented, "These data build upon our previous preclinical cancer studies and provide more evidence for Factor 5A as an anti-cancer agent. It is very heartening to see reduced tumor growth rates in the treated mice."
Future studies may focus on optimizing delivery of Factor 5A to tumors to determine if there would be an enhancement of treatment.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; and competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
Thursday April 27, 6:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--April 27, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today the results of a study conducted in Dr. John Thompson's laboratory at the University of Waterloo in Ontario, Canada, in which mice injected with tumor-forming B16F0 melanoma cancer cells were treated with Senesco's proprietary gene, eIF-5A ("Factor 5A"). Tumors of adequate size formed in approximately nine days at which time treatment was initiated. Two control groups of nine mice each received placebo treatments and a test group of ten mice received Factor 5A, intratumorally, every other day. The median survival of the control mice was 7 days post-treatment, whereas, the mice that received Factor 5A treatment had a median survival of 25 days post-treatment (P less than 0.001). The enhanced survival time of the Factor 5A-treated mice equates to 3.5 fold or a 250% increase compared to the control mice. Two of the Factor 5A-treated mice are still alive, with one mouse in apparent complete remission. None of the control mice survived.
ADVERTISEMENT
In addition to this enhancement of survival, the tumors in the treated mice remained smaller and grew more slowly than those in the control mice.
Dr. Thompson, the Company's Executive Vice President of Research and Development, commented, "These data build upon our previous preclinical cancer studies and provide more evidence for Factor 5A as an anti-cancer agent. It is very heartening to see reduced tumor growth rates in the treated mice."
Future studies may focus on optimizing delivery of Factor 5A to tumors to determine if there would be an enhancement of treatment.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; and competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
senesco ist zu billig!
könnte bis 10$ laufen!
ein ethanol news....dann gehts ab
könnte bis 10$ laufen!
ein ethanol news....dann gehts ab
up
mhhh..
Senesco Technologies Enters into $2.3 Million Equity Financing
Wednesday October 11, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) today announced that on October 10, 2006 it entered into a definitive purchase agreement for the issuance and sale of 1,986,306 shares of its common stock at the closing price of the common stock as of October 9, 2006, expecting to raise approximately $2.3 million in gross proceeds. Approximately $1.5 million of the private placement will be invested by certain members of the Company's Board of Directors, with the balance from certain institutional and accredited investors. In connection with their participation in the private placement, these investors will receive warrants to purchase 993,153 shares of common stock with an exercise price equal to 110% of the common stock purchase price. In connection with this private placement, Senesco has agreed to file a registration statement on Form S-3 by November 10, 2006 to register the shares of common stock and the shares underlying the warrants. The private placement is expected to close on or about today.
The proceeds from the private placement will be used for the Company's ongoing preclinical research programs in cancer and inflammatory diseases, as well as general operating expenses.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The shares of common stock have been sold pursuant to an exemption from state and federal securities laws.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the closing of the private placement; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Joel Brooks, Chief Financial Officer, 732-296-8400
jbrooks@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz or Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
Wednesday October 11, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) today announced that on October 10, 2006 it entered into a definitive purchase agreement for the issuance and sale of 1,986,306 shares of its common stock at the closing price of the common stock as of October 9, 2006, expecting to raise approximately $2.3 million in gross proceeds. Approximately $1.5 million of the private placement will be invested by certain members of the Company's Board of Directors, with the balance from certain institutional and accredited investors. In connection with their participation in the private placement, these investors will receive warrants to purchase 993,153 shares of common stock with an exercise price equal to 110% of the common stock purchase price. In connection with this private placement, Senesco has agreed to file a registration statement on Form S-3 by November 10, 2006 to register the shares of common stock and the shares underlying the warrants. The private placement is expected to close on or about today.
The proceeds from the private placement will be used for the Company's ongoing preclinical research programs in cancer and inflammatory diseases, as well as general operating expenses.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The shares of common stock have been sold pursuant to an exemption from state and federal securities laws.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the closing of the private placement; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Joel Brooks, Chief Financial Officer, 732-296-8400
jbrooks@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz or Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
turnaround!!!!
Hammer News
mit Bayer
Bayer CropScience Licenses Rights to Senesco Technologies' Gene Technology
Thursday November 9, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today that Bayer CropScience has exclusively licensed the rights to Senesco's proprietary gene technology for use in Brassica oilseeds. The agreement anticipates that the licensed technology will enable Bayer CropScience to significantly enhance Canola yields in its InVigor® and future hybrid's business on a global basis. In return, Senesco will receive success-bound development milestone and commercialization payments. Specific financial terms of the transaction were not disclosed.
"Senesco is proud to have Bayer CropScience as a partner for this important crop. We look forward to working with Bayer CropScience due to their marketing strength and commitment to science," said Bruce Galton, President of Senesco.
Dr. Michiel van Lookeren Campagne, Head of Research at BioScience, a business operations unit of Bayer CropScience, welcomes the new business relationship with Senesco: "Bayer CropScience has grown to be a leading company in the canola seed market with InVigor®, our high quality, high yield Canola hybrid varieties. Senesco has shown that the seed yield of Canola can be significantly increased by modulating the expression of its proprietary genes. We anticipate that the innovative Senesco technology will contribute to further strengthen our leadership position in the global hybrid Canola markets."
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey.
About Bayer CropScience
Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 6 billion, is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries.
Your contact:
Bayer CropScience
Annette Josten, phone: +49 2173 38-5788
E-Mail: annette.josten@bayercropscience.com
www.bayercropscience.com
Senesco Technologies, Inc.
Bruce C. Galton, phone: +1 732-296-8400
President & CEO
Email: bgalton@senesco.com
www.senesco.com
Forward-Looking Statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer CropScience AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future consolidated results, financial situation, development or performance of the Bayer CropScience AG or our parent company, Bayer AG, and the estimates given here. These factors include those discussed in Bayer AG's public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Bayer AG's Form 20-F). Neither Bayer AG nor Bayer CropScience AG assumes any liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For Senesco: Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
Chief Executive Officer
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
mit Bayer
Bayer CropScience Licenses Rights to Senesco Technologies' Gene Technology
Thursday November 9, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today that Bayer CropScience has exclusively licensed the rights to Senesco's proprietary gene technology for use in Brassica oilseeds. The agreement anticipates that the licensed technology will enable Bayer CropScience to significantly enhance Canola yields in its InVigor® and future hybrid's business on a global basis. In return, Senesco will receive success-bound development milestone and commercialization payments. Specific financial terms of the transaction were not disclosed.
"Senesco is proud to have Bayer CropScience as a partner for this important crop. We look forward to working with Bayer CropScience due to their marketing strength and commitment to science," said Bruce Galton, President of Senesco.
Dr. Michiel van Lookeren Campagne, Head of Research at BioScience, a business operations unit of Bayer CropScience, welcomes the new business relationship with Senesco: "Bayer CropScience has grown to be a leading company in the canola seed market with InVigor®, our high quality, high yield Canola hybrid varieties. Senesco has shown that the seed yield of Canola can be significantly increased by modulating the expression of its proprietary genes. We anticipate that the innovative Senesco technology will contribute to further strengthen our leadership position in the global hybrid Canola markets."
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey.
About Bayer CropScience
Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 6 billion, is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries.
Your contact:
Bayer CropScience
Annette Josten, phone: +49 2173 38-5788
E-Mail: annette.josten@bayercropscience.com
www.bayercropscience.com
Senesco Technologies, Inc.
Bruce C. Galton, phone: +1 732-296-8400
President & CEO
Email: bgalton@senesco.com
www.senesco.com
Forward-Looking Statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer CropScience AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future consolidated results, financial situation, development or performance of the Bayer CropScience AG or our parent company, Bayer AG, and the estimates given here. These factors include those discussed in Bayer AG's public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Bayer AG's Form 20-F). Neither Bayer AG nor Bayer CropScience AG assumes any liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For Senesco: Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
Chief Executive Officer
bgalton@senesco.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
kgolodetz@lhai.com
afields@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
gestern gabs wieder einen insiderkauf
Purchase 2006-11-29 2006-11-30
09:12:33 SENESCO TECHNOLOGIES INC SNT STALDER RUEDI Director 10,000 $1.159 $11,590 211,771 Direct
Purchase 2006-11-29 2006-11-30
09:12:33 SENESCO TECHNOLOGIES INC SNT STALDER RUEDI Director 10,000 $1.159 $11,590 211,771 Direct
Senesco Technologies Executes Licensing Deal with ArborGen
Thursday December 28, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) and ArborGen, LLC, the Company's forestry product co-development partner, announced the execution of a licensing agreement for exclusive use of the company's technology for the enhancement of forestry products. Execution of the agreement follows ArborGen's decision, announced in June 2006, to exercise its option to license Senesco's technology based on positive field trial results.
As previously announced, Senesco and ArborGen have collaborated over the past four years in an effort to develop trees with greater biomass and shorter time to harvest. After three years of positive lab and greenhouse results, trees were established in the field in August 2004. At the end of the 2005 growing season, certain trees which were enhanced by the Senesco technology had approximately double the increase in volume relative to control trees.
Financial terms of the agreement were not disclosed.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
About ArborGen, LLC.
ArborGen LLC, with headquarters in Summerville, SC, is a global leader in the research, development and commercialization of genetic technologies that will improve forest sustainability and productivity. ArborGen is developing commercially important technologies that will lead to improved forest management systems and forest product manufacturing processes. We are producing faster growing and sturdier trees that use less land and energy to process and will meet increasing wood product needs of a growing population. Growing these trees on planted forests offers the potential to protect and replenish native forests in all their diversity and complexity.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, Chief Executive Officer, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contact:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
Thursday December 28, 7:00 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) and ArborGen, LLC, the Company's forestry product co-development partner, announced the execution of a licensing agreement for exclusive use of the company's technology for the enhancement of forestry products. Execution of the agreement follows ArborGen's decision, announced in June 2006, to exercise its option to license Senesco's technology based on positive field trial results.
As previously announced, Senesco and ArborGen have collaborated over the past four years in an effort to develop trees with greater biomass and shorter time to harvest. After three years of positive lab and greenhouse results, trees were established in the field in August 2004. At the end of the 2005 growing season, certain trees which were enhanced by the Senesco technology had approximately double the increase in volume relative to control trees.
Financial terms of the agreement were not disclosed.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
About ArborGen, LLC.
ArborGen LLC, with headquarters in Summerville, SC, is a global leader in the research, development and commercialization of genetic technologies that will improve forest sustainability and productivity. ArborGen is developing commercially important technologies that will lead to improved forest management systems and forest product manufacturing processes. We are producing faster growing and sturdier trees that use less land and energy to process and will meet increasing wood product needs of a growing population. Growing these trees on planted forests offers the potential to protect and replenish native forests in all their diversity and complexity.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, Chief Executive Officer, 732-296-8400
bgalton@senesco.com
or
Investor Relations Contact:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 196 | ||
| 93 | ||
| 65 | ||
| 50 | ||
| 46 | ||
| 43 | ||
| 42 | ||
| 37 | ||
| 33 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 15 | ||
| 15 |
